Here’s a question that frequently arises in clinics, online forums, and consultations: “Should I choose Mounjaro or Ozempic?”
Both are weekly injectables targeting hunger and blood sugar hormones, but they’re not identical. Ozempic (semaglutide, a GLP-1 agonist) is approved mainly for type 2 diabetes, with strong weight-loss effects (Wegovy is its dedicated weight version). Mounjaro (tirzepatide) is a dual GLP-1/GIP agonist, approved for diabetes (Zepbound for weight loss), and often delivers greater average weight loss (15–22% vs. 10–15%) and better blood sugar control in studies.
Side effects (nausea, diarrhea, etc.) are similar, though profiles vary slightly. Cost is comparable ($1,000–$1,500/month without insurance).
Neither is universally better—it depends on your goals, health history, and doctor’s advice. Mounjaro often edges out in effectiveness for many, but results vary. Always consult a healthcare provider. (68 words)
The gap in weight loss outcomes between Mounjaro (tirzepatide) and Ozempic (semaglutide 1mg) is wider than most people realise. Understanding why that gap exists — and what it means for you — is what this guide is for. We’ll cover the clinical data, the real-world picture in 2026, costs, side effects, and which patients each treatment tends to suit best.
One thing up front: this is not a case of one medication being universally ‘better’. The right choice depends on your health history, your goals, and frankly, what’s available to you. Let’s get into it.
Mounjaro vs Ozempic: Quick Comparison (2026)
We’ve also included Wegovy (semaglutide 2.4mg) and Saxenda (liraglutide) in the broader context of this article, but the table below focuses on the two drugs you’re here to compare.
| Mounjaro (tirzepatide) | Ozempic (semaglutide 1mg) | Key difference | |
| Drug class | GIP + GLP-1 agonist | GLP-1 agonist only | Mounjaro targets 2 hormones |
| Licensed use | Weight management (UK) | Type 2 diabetes (UK) | Ozempic = off-label for weight loss |
| Avg weight loss | ~20–22% | ~5–8%* | Mounjaro ~3× more weight lost |
| Injection frequency | Once weekly | Once weekly | Same convenience |
| Dose range | 2.5mg → 15mg | 0.25mg → 1mg | Very different dose scales |
| Cardiovascular data | Pending (SURPASS-CVOT) | Strong (SELECT trial) | Ozempic has more CV evidence |
| NHS availability | Limited pilot | Diabetes only | Neither widely available for weight loss |
| Approx. private cost/mo | £150–£250 | £80–£140 | Ozempic often cheaper |
*Ozempic weight loss figures are from diabetes trials — it is not licensed for weight management.
The Fundamental Difference: Two Hormones vs One
Both drugs belong to the GLP-1 receptor agonist class — a group of medications that mimic the gut hormone GLP-1 (glucagon-like peptide-1), which signals fullness to the brain, slows gastric emptying, and helps regulate blood sugar. This mechanism is well-established, and it’s why semaglutide-based drugs like Ozempic and Wegovy produce meaningful weight loss.
Mounjaro does all of this — and adds a second mechanism. Tirzepatide also activates the GIP receptor (glucose-dependent insulinotropic polypeptide), another gut hormone involved in insulin release, fat storage, and energy metabolism. This dual agonism — targeting both GLP-1 and GIP simultaneously — is the pharmacological reason Mounjaro consistently outperforms single-agent GLP-1 drugs in trials.
In practical terms: Ozempic is telling your body one thing. Mounjaro is telling it two things at once, and the combined signal appears to produce a stronger metabolic response. The analogy isn’t perfect, but think of it as the difference between pressing one brake and two — the deceleration is meaningfully different.
What the Clinical Evidence Actually Says
Mounjaro (Tirzepatide) — SURMOUNT Trial Data
The benchmark trial for tirzepatide in obesity is SURMOUNT-1, published in the New England Journal of Medicine. In adults with obesity but without type 2 diabetes, those on the highest dose (15mg weekly) achieved average weight loss of 20.9% of body weight over 72 weeks — roughly equivalent to bariatric surgery outcomes for many patients.
Even at the lowest studied dose (5mg), participants lost an average of 16% of body weight. Around one in three patients on the highest dose lost 25% or more. These numbers were described by obesity medicine specialists as genuinely unprecedented for a pharmacological treatment.
In patients with type 2 diabetes (the SURMOUNT-2 trial), results were slightly lower — around 15% weight loss at the highest dose — but still substantially greater than comparator drugs.
Ozempic (Semaglutide 1mg) — What the Data Shows
Ozempic was developed and licensed as a diabetes treatment, not a weight management drug. That distinction matters enormously when interpreting the data. In the SUSTAIN clinical trial programme, semaglutide 1mg produced average weight loss of around 4–6kg — roughly 5–8% of body weight — in patients with type 2 diabetes.
When researchers tested a higher dose of semaglutide specifically designed for weight loss — 2.4mg weekly, branded as Wegovy — average weight loss jumped to 14.9% in the STEP trials. This is an important distinction: Ozempic at 1mg is not the same as Wegovy at 2.4mg, even though they contain the same molecule. The dose makes a substantial difference.
Many people ask whether taking Ozempic off-label for weight loss makes sense. It can produce meaningful results, particularly in people with insulin resistance or prediabetes. But the data suggests the weight loss ceiling at 1mg is considerably lower than what tirzepatide or higher-dose semaglutide can achieve.
The Head-to-Head: SURMOUNT-5
The most important recent data comes from the SURMOUNT-5 trial, the first properly controlled head-to-head comparison of tirzepatide (at weight loss doses) against semaglutide (at weight loss doses). The results, published in 2024, showed average weight loss of 20.2% with tirzepatide vs 13.7% with semaglutide 2.4mg. Participants on tirzepatide were also significantly more likely to achieve 25% weight loss.
It’s worth noting that SURMOUNT-5 compared Mounjaro to Wegovy (2.4mg) — not to Ozempic (1mg). The gap between Mounjaro and Ozempic at its licensed diabetes dose is therefore likely even larger.
Licensed Use vs Off-Label Prescribing: Why It Matters
This is one of the most misunderstood parts of the Mounjaro vs Ozempic conversation, and it has real implications for UK patients.
Mounjaro received MHRA approval in the UK for chronic weight management in November 2023. It is a licensed weight loss treatment. According to NICE guidance on tirzepatide, it is recommended for adults with a BMI of 35 or above (or 30 with certain conditions) as part of a specialist weight management programme.
Ozempic, by contrast, is licensed in the UK for the treatment of type 2 diabetes — not for weight management. Any prescribing of Ozempic for weight loss is off-label. This isn’t illegal, and off-label prescribing is common in medicine, but it means the drug hasn’t gone through the same regulatory review for that specific use. It also affects NHS prescribing and insurance coverage.
If weight management is your primary goal and you meet eligibility criteria, there’s a strong clinical argument for using a drug that’s actually licensed for that purpose — whether that’s Mounjaro, Wegovy, or Saxenda (liraglutide).
Side Effects: How Do They Compare?
Both tirzepatide and semaglutide share a broadly similar side effect profile, driven by their shared GLP-1 mechanism. The most common complaints are gastrointestinal — and for most people, they’re temporary.
Common Side Effects (Both Drugs)
- Nausea — most common during dose escalation, usually improves
- Vomiting — typically peaks in the first few weeks
- Diarrhoea or constipation — often alternating
- Reduced appetite — this is also the therapeutic mechanism, so expected
- Fatigue, particularly early on
Differences to Be Aware Of
People switching from Ozempic to Mounjaro often report that side effects feel more pronounced initially with tirzepatide — likely because the dual hormone mechanism creates a stronger physiological response. The good news is that Mounjaro uses the same slow dose-escalation approach, starting at 2.5mg and titrating upward every four weeks, which helps manage tolerability.
Both drugs carry a theoretical risk of thyroid C-cell tumours based on animal studies. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. These warnings are consistent across the class — they’re not unique to either drug.
The FDA prescribing information for Ozempic and the equivalent documentation for Mounjaro both outline contraindications in detail. Reviewing these with your prescriber before starting is essential.
Cardiovascular Benefits: A Key Point of Difference in 2026
One area where Ozempic (and its higher-dose cousin Wegovy) currently has an advantage over Mounjaro is cardiovascular outcome data.
The SELECT trial, published in 2023, demonstrated that semaglutide 2.4mg reduced the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in patients with existing cardiovascular disease and obesity — independent of weight loss. This was a landmark result that significantly strengthened the case for semaglutide-based treatment in high-risk patients.
For Mounjaro, the equivalent cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. Early signals are promising — particularly given tirzepatide’s strong effects on blood pressure, lipids, and blood sugar — but we don’t yet have the same volume of hard cardiovascular outcome data for tirzepatide that we do for semaglutide.
If you have existing heart disease or are considered high cardiovascular risk, your cardiologist or GP may favour semaglutide-based treatment for now, specifically for the SELECT trial data. This is a genuinely important clinical consideration in 2026.
Who Should Consider Mounjaro vs Ozempic?
Mounjaro May Be More Appropriate If…
- Weight loss is your primary goal and you meet eligibility criteria — tirzepatide is the most effective licensed option currently available
- You have type 2 diabetes or significant insulin resistance — the dual GIP/GLP-1 mechanism offers additional metabolic benefits
- You have a higher starting BMI (typically 35+) and are targeting substantial weight reduction
- You’ve tried semaglutide and found the results insufficient — many clinicians consider tirzepatide a logical next step
Ozempic May Be More Appropriate If…
- You have type 2 diabetes and weight loss is a secondary — rather than primary — goal alongside glycaemic control
- You have established cardiovascular disease and your clinician wants to leverage the SELECT trial outcome data
- Cost is a significant barrier — Ozempic is often more affordable privately, and is available on NHS for diabetes
- You’re monitoring supply availability — Ozempic has a longer prescribing history and slightly more stable supply chains in some regions
It’s also worth noting that if weight management is your goal and you don’t have diabetes, Wegovy (semaglutide 2.4mg) is a better semaglutide option than Ozempic — it’s the licensed weight loss version of the same molecule at a higher, more effective dose. You can find a detailed breakdown in our [Internal Link: Mounjaro vs Wegovy comparison article].
Cost and Availability in the UK — 2026 Update
The prescribing landscape for both drugs continues to evolve. As of 2026, here’s the honest picture for UK patients:
On the NHS: Ozempic is available on NHS prescription for type 2 diabetes. Mounjaro has limited NHS availability through specialist NHS weight management services following NICE approval. Neither is yet available as a routine GP prescription for weight loss, though this is expected to change as NHS rollout progresses.
Privately: Both are accessible via private prescription through registered online clinics and specialist providers. Approximate monthly costs:
- Mounjaro: £150–£250/month depending on dose (higher doses cost more)
- Ozempic: £80–£140/month (though supply can fluctuate due to diabetes demand)
- Wegovy: £150–£230/month
- Saxenda: £120–£180/month — worth comparing if daily injection is acceptable
Ozempic’s lower private cost is partly why it remains popular for off-label weight loss prescribing. But cost savings need to be weighed against the fact that you’ll likely be getting a lower-dose, unlicensed-for-weight-loss product. Discuss this trade-off explicitly with your prescriber.
Supply shortages have periodically affected both drugs. The MHRA has issued guidance on supply management, and reputable prescribers will have processes in place if your regular brand becomes temporarily unavailable.
Frequently Asked Questions
Q: Is Mounjaro stronger than Ozempic for weight loss?
Yes — significantly so, based on the available clinical data. Mounjaro (tirzepatide) produces average weight loss of around 20% of body weight at its highest dose, compared to approximately 5–8% with Ozempic (semaglutide 1mg) in diabetes patients. The gap exists for two reasons: tirzepatide targets both GLP-1 and GIP receptors (Ozempic targets only GLP-1), and Ozempic is dosed at 1mg for diabetes rather than the higher doses used in weight management trials. For the fairest comparison, Mounjaro should be compared to Wegovy (semaglutide 2.4mg) — even then, tirzepatide outperforms.
Q: Can I use Ozempic for weight loss if I don’t have diabetes?
Yes, but it would be an off-label prescription. Ozempic is licensed in the UK for type 2 diabetes, not weight management. A prescriber can legally prescribe it off-label for weight loss, but it’s worth knowing that the licensed alternative — Wegovy (semaglutide 2.4mg) — uses the same molecule at a higher, more effective dose and has gone through formal regulatory approval for weight management. If your goal is weight loss, Wegovy or Mounjaro are generally more clinically appropriate choices.
Q: What is the difference between Ozempic and Wegovy?
Both contain semaglutide, but they are different products. Ozempic is licensed for type 2 diabetes and uses doses of 0.5mg or 1mg weekly. Wegovy is licensed specifically for chronic weight management and uses a higher dose of up to 2.4mg weekly. Wegovy’s higher dose is what drives its superior weight loss outcomes — average 15% vs 5–8% for Ozempic. If you’re being offered semaglutide for weight loss, confirm whether it’s Wegovy (2.4mg) or Ozempic (1mg) — the distinction matters considerably.
Q: Can I switch from Ozempic to Mounjaro?
Many patients do transition from semaglutide-based treatment to tirzepatide, particularly if initial results are insufficient or plateauing. The switch needs to be managed by a prescriber who can guide dose titration — you typically start Mounjaro at the lowest dose (2.5mg) regardless of what you were taking before, to allow your body to adjust. There’s no evidence of serious safety issues in switching between these drugs, but it should always be done under medical supervision.
Q: Does Ozempic have more cardiovascular evidence than Mounjaro?
Currently, yes. The SELECT trial demonstrated a 20% reduction in major cardiovascular events with semaglutide 2.4mg in patients with obesity and pre-existing cardiovascular disease. This was a landmark finding. Mounjaro’s cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing. Early data is promising, but semaglutide currently has the more robust cardiovascular evidence base. If you have significant heart disease, your clinician may factor this into their recommendation.
Q: How long does it take to see results on Mounjaro or Ozempic?
Most people notice reduced appetite within the first 2–4 weeks of starting either treatment. Visible weight loss typically becomes more apparent from weeks 8–12 onwards, as the dose is gradually increased. Both medications use an escalating dose schedule — starting low and titrating upward — to minimise side effects. Meaningful, sustained weight loss continues over 6–12+ months. Results vary depending on diet, physical activity, starting weight, and individual metabolic response. Neither drug is a quick fix — they work best as part of a structured lifestyle programme.
